Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 21, 2014; 20(47): 17976-17984
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17976
Published online Dec 21, 2014. doi: 10.3748/wjg.v20.i47.17976
Table 4 Total costs for patients undergoing adjuvant chemotherapy
| Parameters | FOLFOX4 ($) | XELOX ($) | Data source |
| Direct costs/mo | 3314.16 ± 713.38 | 3018.88 ± 520.37 | Xie et al[14] and others, 2013 |
| Adverse event costs/mo | 145.62 ± 4.6 | 34.13 ± 2.8 | |
| Societal costs/mo | 3558.78 | 3082.5 | |
| Cost for well state (Cw1/Cw2) | 6872.94 ± 713.38 | 6101.38 ± 520.37 | |
| Cost for minor toxicity state (Cmi1/Cmi2) | Cw1 | Cw2 | |
| Cost for major toxicity state (Cma1/Cma2) | 7018.56 ± 717.98 | 6135.50 ± 523.17 | |
| Cost for quitting adjuvant chemotherapy (Cq1/Cq2) | Cma1 | Cma2 |
- Citation: Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials. World J Gastroenterol 2014; 20(47): 17976-17984
- URL: https://www.wjgnet.com/1007-9327/full/v20/i47/17976.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i47.17976